CALR mutation screening in pediatric primary myelofibrosis
Wenbin An(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaofan Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuanyuan Ren(Yangtze University), Yang Wan(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Wei(Zhujiang Hospital), Xiaojuan Chen(Central South University), Peihong Zhang(Tongji University), Ye Guo(Army Medical University), Lixian Chang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingliao Zhang(St. Jude Children's Research Hospital)
Cited by 25
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
|Blood|2019|307
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|JAMA Oncology|2020|245
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216